Cryptocurrency Policy
-
The Current State of Virtual Currency Trading Platforms in Mainland China: No “Legitimate” Platforms; High Risks for Overseas Participants
Mainland China has implemented a comprehensive ban on cryptocurrency trading and related activities; since 2021, there have been no “official” or legally operating cryptocurrency trading platform apps within the country. In February 2026, regulators further reaffirmed and strengthened the ban, clarifying that services provided by overseas platforms to residents within the country also constitute illegal financial activities. Users in mainland China who engage in trading through overseas platforms face serious legal and financial risks.
- No data
-
The Current State of Virtual Currency Trading Platforms in Mainland China: No “Legitimate” Platforms; High Risks for Overseas Participants
Mainland China has implemented a comprehensive ban on cryptocurrency trading and related activities; since 2021, there have been no “official” or legally operating cryptocurrency trading platform apps within the country. In February 2026, regulators further reaffirmed and strengthened the ban, clarifying that services provided by overseas platforms to residents within the country also constitute illegal financial activities. Users in mainland China who engage in trading through overseas platforms face serious legal and financial risks.
Cryptocurrency Policy
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
7
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading








